News
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
OncLive® National Fellows Forum: Lung Cancer 2023
Join us in Chicago for Giants of Cancer Care®
Specialty
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
OncClub
All Oncology News
Pipeline Report
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conference Coverage
Conference Listing
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Interactive Tools
Learning Modules
Presentations
Sponsored
Print Subscription
eNewsletter
Advertisement
Urothelial Cancer
| Breast Cancer
| Lung Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Ovarian Cancer
| Prostate Cancer
| Melanoma & Skin Cancer
| Mantle Cell Lymphoma
| Myeloproliferative Neoplasms
| Biosimilars
| Brain Cancer
| Business Management
| CAR T-cell Therapy
| COVID-19
| Chronic Lymphocytic Leukemia
| Colorectal Cancer
| Disparities in Cancer Care
| Global Oncology
| Gynecologic Oncology
| Head & Neck Cancers
| Hematologic Oncology
| Immuno-Oncology
| Multiple Myeloma
| Neoadjuvant HER2+
| Non-Hodgkin Lymphoma
| Oncology Nursing News
| Pediatric Oncology
| Precision Medicine in Oncology®
| Sarcomas/TGCT
| Supportive Care
View All >>
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
  • Business Management
  • CAR T-cell Therapy
  • COVID-19
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Global Oncology
  • Gynecologic Oncology
  • Head & Neck Cancers
  • Hematologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Mantle Cell Lymphoma
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Neoadjuvant HER2+
  • Non-Hodgkin Lymphoma
  • Oncology Nursing News
  • Ovarian Cancer
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Prostate Cancer
  • Sarcomas/TGCT
  • Supportive Care
  • Urothelial Cancer

SPOTLIGHT -

OncLive® National Fellows Forum: Lung Cancer 2023
| Join us in Chicago for Giants of Cancer Care®
Update on EGFR Antibodies in mCRC : Episode 1

Trends in Colorectal Cancer Incidence

May 25, 2021
Zev A. Wainberg, MD, UCLA
Jaffer A. Ajani, MD, MD Anderson Cancer Center
Supplements And Featured PublicationsMy Treatment Approach: Colorectal Cancer
Volume 1
Issue 1

Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.

Now Viewing

EP: 1.Trends in Colorectal Cancer Incidence

EP: 2.Molecular Testing in Metastatic Colorectal Cancer

EP: 3.Next-Generation Sequencing in Metastatic Colorectal Cancer

EP: 4.Selecting Systemic Therapy for Newly Diagnosed mCRC

EP: 5.Changes in Cetuximab Dosing Schedule in mCRC

EP: 6.Sequencing Anti-EGFR Therapy in mCRC

EP: 7.Later-Line Treatment Options for mCRC

EP: 8.EGFR Therapy for mCRC: Dermatologic Toxicity

EP: 9.Future Directions in mCRC

EP: 10.KRAS G12C Inhibitors in mCRC

Zev A. Wainberg, MD: Hi, it’s a pleasure to be here at this OncLive® filming. My name is Dr Zev Wainberg from UCLA [the University of California, Los Angeles], and I’m very pleased to be joined here by my good friend and colleague Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center. Today we’re going to be discussing a number of topics related to colorectal cancer, with some of the recent trends in epidemiology and demographics of this disease, as well as some recent labeling changes in some of the monoclonal antibodies used. Let’s begin. Dr Ajani, I wonder if you could talk a little bit about some of the recent trends, survival, demographics, and epidemiology of metastatic colon cancer.

Jaffer A. Ajani, MD: It’s a real pleasure for me to participate this evening. Colorectal cancer remains a significant problem globally. There are almost 1.8 million new cases and 700,000 deaths each year. And since 1990, the incidence in people younger than 50 has been rising almost 2%. There were several thousand deaths recorded in 2020 in that age group, and we don’t know what is going on there. There’s some suspicion that younger people are more sedentary than they used to be and that processed food and obesity may be responsible, but it’s a real mystery and very alarming situation. Overall, the incidence of colorectal cancer has gone down. Some of the early detection strategies have worked, but it’s still hard to motivate individuals. I’m hoping that as we go forward that liquid biopsy will provide a better opportunity for early detection.

Zev A. Wainberg, MD: It’s been interesting that we see the population steadily decrease. We’re seeing more and more younger people under the age of 45, particularly in rectal cancer, and even in circumstances where presumably these are active people who eat well, we still see this unusual epidemiologic trend, which is very alarming. It’s good to see the screening societies take notice because as you know, they changed the recommendation earlier this year to allow for screening colonoscopies in anybody over 45, down from 50 previously. That’s a big deal when a screening society changes its recommendation.

Transcript Edited for Clarity

Articles in this issue

Ardaman Shergill, MD
Anti-EGFR/Chemo Combos Allow for Tailored Approach in mCRC
Richard Kim, MD
Biweekly Cetuximab Offers a Convenient Dosing Option in mCRC
Zev A. Wainberg, MD
GI Experts Discuss Treatment Dosing, Sequencing, and Future Directions in CRC
Zev A. Wainberg, MD
Genomics, Sidedness Guide Treatment Selection in Metastatic CRC
KRAS G12C Inhibitors in mCRC
KRAS G12C Inhibitors in mCRC
Future Directions in mCRC
Future Directions in mCRC
EGFR Therapy for mCRC: Dermatologic Toxicity
EGFR Therapy for mCRC: Dermatologic Toxicity
Later-Line Treatment Options for mCRC
Later-Line Treatment Options for mCRC
Sequencing Anti-EGFR Therapy in mCRC
Sequencing Anti-EGFR Therapy in mCRC
Changes in Cetuximab Dosing Schedule in mCRC
Changes in Cetuximab Dosing Schedule in mCRC
Selecting Systemic Therapy for Newly Diagnosed mCRC
Selecting Systemic Therapy for Newly Diagnosed mCRC
Next-Generation Sequencing in Metastatic Colorectal Cancer
Next-Generation Sequencing in Metastatic Colorectal Cancer
Molecular Testing in Metastatic Colorectal Cancer
Molecular Testing in Metastatic Colorectal Cancer
Trends in Colorectal Cancer Incidence
Trends in Colorectal Cancer Incidence
Related Videos
In this fifth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, highlights progress made with regard to colon cancer treatment and Lynch syndrome, including leveraging immunotherapy.
In this fourth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, explains the implications of Lynch syndrome genotype on risk of colorectal cancer.
Brian C. Grieb, MD, PhD
John L. Hays, MD, PhD
Brian C. Grieb, MD, PhD
Alaa Muslimani, MD
In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, discusses testing guidance for identifying Lynch syndrome.
Mariana X. Byndloss, DVM, PhD
In this second episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, delves into the epidemiology of Lynch syndrome, the pathogenic variants in the mismatch-repair genes that cause the condition, and criteria utilized to identify it.
Yonina R. Murciano-Goroff, MD, MSc, DPhil
Related Content

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

FDA Grants Priority Review to Fruquintinib for Previously Treated mCRC

May 25th 2023

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC

May 17th 2023

Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC

May 16th 2023

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

FDA Grants Priority Review to Fruquintinib for Previously Treated mCRC

May 25th 2023

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC

May 17th 2023

Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC

May 16th 2023

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

FDA Grants Priority Review to Fruquintinib for Previously Treated mCRC

May 25th 2023

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC

May 17th 2023

Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC

May 16th 2023
Related Content
Jane Meisel, MD

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
The FDA has granted priority review to the new drug application seeking the approval of fruquintinib for use in the treatment of adult patients with previously treated metastatic colorectal cancer.

FDA Grants Priority Review to Fruquintinib for Previously Treated mCRC

May 25th 2023
Article
Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022
Podcast
Colorectal Cancer

Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC

May 17th 2023
Article
Jayesh Desai, MBBS, FRACP

Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC

May 16th 2023
Article

Latest Conference Coverage

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact